Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINATION study of RO7434656 in primary IgA nephropathy at high risk of progression
CTR20233981Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sefaxersen in IgA nephropathy (IgAN), sponsored by Roche. Started Apr 2024; status: active.
02
Drugs
sefaxersen
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20233981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233981.